Funding and financial sustainability of pharmacovigilance: suggested models for funding pharmacovigilance in resource-limited African countries.

Authors:
Isah AO; Opadeyi AO; Tumwijukye H; Cobelens F; Smith D and 9 more

Journal:
Ther Adv Drug Saf

Publication Year: 2023

DOI:
10.1177/20420986231188836

PMCID:
PMC10387667

PMID:
37529763

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Ther Adv Drug Saf

Abbreviation: Ther Adv Drug Saf

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Direct oral anticoagulant use in hospitalized patients with atrial fibrillation across body mass in…
Shaikh F; Wynne R; L Castelino R and 3 more (2024) - Transparency Score: 3/6
Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Eve…
Jiang T; Su H; Xu J and 9 more (2024) - Transparency Score: 3/6
Acceptability of a cross-sectoral hospital pharmacist intervention for patients in transition betwe…
Sørensen CA; Jeffery L; Roelsgaard K and 4 more (2023) - Transparency Score: 3/6
Analysis of the nature and contributory factors of medication safety incidents following hospital d…
Alqenae FA; Steinke D; Carson-Stevens A and 1 more (2023) - Transparency Score: 3/6
Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance u…
Altebainawi AF; Alfaraj LA; Alharbi AA and 2 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"The authors declare that there is no conflict of interest."

Evidence found in paper:

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This publication was produced by PAVIA which is part of the EDCTP2 programme supported by the European Union (grant number CSA2016S-1627 – PAVIA). The views and opinions of authors expressed herein do not necessarily state or reflect those of EDCTP. The funding of PAVIA by the EDCTP is gratefully acknowledged."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025